Mizuho Boosts Lantheus (NASDAQ:LNTH) Price Target to $85.00

Lantheus (NASDAQ:LNTH) had its price target hoisted by Mizuho from $72.00 to $85.00 in a report issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Mizuho’s price target indicates a potential upside of 13.47% from the stock’s previous close.

LNTH has been the subject of several other research reports. JonesTrading cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday. Truist Financial boosted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday. Citigroup reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Price Performance

LNTH opened at $74.91 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The stock’s 50 day simple moving average is $68.15 and its 200 day simple moving average is $60.19. The firm has a market cap of $4.97 billion, a price-to-earnings ratio of 22.23 and a beta of -0.08. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.37% and a net margin of 15.15%.The firm had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same quarter in the previous year, the company posted $1.59 earnings per share. The business’s revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts predict that Lantheus will post 6.01 earnings per share for the current year.

Hedge Funds Weigh In On Lantheus

Institutional investors have recently bought and sold shares of the stock. Villanova Investment Management Co LLC purchased a new stake in Lantheus in the fourth quarter worth about $1,511,000. Alberta Investment Management Corp bought a new position in shares of Lantheus in the 4th quarter worth approximately $1,617,000. Vident Advisory LLC lifted its stake in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after purchasing an additional 230 shares during the period. Mackenzie Financial Corp boosted its position in shares of Lantheus by 31.1% during the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock valued at $44,082,000 after purchasing an additional 156,081 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in Lantheus by 64.8% in the fourth quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock worth $1,227,000 after purchasing an additional 7,252 shares during the period. 99.06% of the stock is owned by institutional investors.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.